fda warning letters compounding semaglutide september 2025 A company called Nomida has received an letter for offering for sale injectable weight-loss treatments. None of their offerings are FDA- approved. Nomida is allegedly selling unapproved and Tirzepatide "kits" FDA Targets GLP-1 and Peptide

M.MorimotoH

Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes

Read Patient Experiences with Zoladex FDA Announces New Safety Warning for Radiofrequency (RF) Microneedling Devices In a safety communication, the FDA warned about the risk of serious side effects from procedures using radiofrequency (RF) microneedling devices, which are marketed for facial wrinkles, abdominal scars, or acne scar improvement

These drugs seem to dampen the reward response, which also may reduce addictive behaviors like cravings for alcohol, sugar, and nicotine," Dr

TSA: Traveling with Diabetes Medications , Transportation Security Administration

This aggressive but controlled ramp-up helps the body adjust to the triple receptor activation while minimizing the gastrointestinal distress that comes with too-rapid dose increases